120 related articles for article (PubMed ID: 35276694)
1. Mechanisms of GZ17-6.02 resistance.
Booth L; West C; Von Hoff D; Dent P
Anticancer Drugs; 2022 Jun; 33(5):415-423. PubMed ID: 35276694
[TBL] [Abstract][Full Text] [Related]
2. GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.
Booth L; Roberts JL; West C; Von Hoff D; Dent P
J Cell Physiol; 2020 Nov; 235(11):8098-8113. PubMed ID: 31951027
[TBL] [Abstract][Full Text] [Related]
3. GZ17-6.02 kills PDX isolates of uveal melanoma.
Booth L; Roberts JL; Spasojevic I; Baker KC; Poklepovic A; West C; Kirkwood JM; Dent P
Oncotarget; 2024 May; 15():328-344. PubMed ID: 38758815
[TBL] [Abstract][Full Text] [Related]
4. GZ17-6.02 and axitinib interact to kill renal carcinoma cells.
Booth L; West C; Moore RP; Hoff DV; Dent P
Oncotarget; 2022; 13():281-290. PubMed ID: 35136485
[TBL] [Abstract][Full Text] [Related]
5. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells.
Booth L; West C; Von Hoff D; Kirkwood JM; Dent P
Front Oncol; 2021; 11():656453. PubMed ID: 33898322
[TBL] [Abstract][Full Text] [Related]
6. GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.
Booth L; Roberts JL; West C; Dent P
Oncotarget; 2024 Mar; 15():159-174. PubMed ID: 38441437
[TBL] [Abstract][Full Text] [Related]
7. GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.
Booth L; West C; Moore RP; Von Hoff D; Dent P
Oncotarget; 2022; 13():92-104. PubMed ID: 35035775
[TBL] [Abstract][Full Text] [Related]
8. GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.
Booth MR; Booth L; Roberts JL; West C; Dent P
Oncotarget; 2024 Feb; 15():124-133. PubMed ID: 38329728
[TBL] [Abstract][Full Text] [Related]
9. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
[TBL] [Abstract][Full Text] [Related]
10. GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins.
Booth L; West C; Moore RP; Von Hoff D; Dent P
Front Oncol; 2021; 11():711043. PubMed ID: 34490108
[TBL] [Abstract][Full Text] [Related]
11. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
Dent P; Booth L; Poklepovic A; Hoff DV; Hancock JF
Cell Signal; 2020 Apr; 68():109525. PubMed ID: 31911180
[TBL] [Abstract][Full Text] [Related]
12. GZ17-6.02 kills prostate cancer cells
Booth L; Roberts JL; West C; Dent P
Front Oncol; 2022; 12():1045459. PubMed ID: 36408163
[TBL] [Abstract][Full Text] [Related]
13. Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds.
Vishwakarma V; New J; Kumar D; Snyder V; Arnold L; Nissen E; Hu Q; Cheng N; Miller D; Thomas AR; Shnayder Y; Kakarala K; Tsue TT; Girod DA; Thomas SM
Sci Rep; 2018 Aug; 8(1):12163. PubMed ID: 30111862
[TBL] [Abstract][Full Text] [Related]
14. (Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
J Cell Physiol; 2020 Oct; 235(10):6862-6874. PubMed ID: 31985048
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Huang X; Wang S; Lee CK; Yang X; Liu B
Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
[TBL] [Abstract][Full Text] [Related]
16. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
[TBL] [Abstract][Full Text] [Related]
17. GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling.
Booth L; West C; Hoff DV; Dent P
Front Oncol; 2020; 10():1331. PubMed ID: 32983965
[TBL] [Abstract][Full Text] [Related]
18. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Booth L; Poklepovic A; Dent P
Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
[TBL] [Abstract][Full Text] [Related]
19. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
Chen X; Yeung TK; Wang Z
Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
[TBL] [Abstract][Full Text] [Related]
20. GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma.
Choi J; Bordeaux ZA; McKeel J; Nanni C; Sutaria N; Braun G; Davis C; Miller MN; Alphonse MP; Kwatra SG; West CE; Kwatra MM
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
